{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:28:28Z","timestamp":1761895708354},"reference-count":64,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,9]]},"DOI":"10.1097\/cco.0b013e328363df0b","type":"journal-article","created":{"date-parts":[[2013,7,19]],"date-time":"2013-07-19T10:42:01Z","timestamp":1374230521000},"page":"452-462","source":"Crossref","is-referenced-by-count":5,"title":["The current therapeutic scenario for relapsed mantle cell lymphoma"],"prefix":"10.1097","volume":"25","author":[{"given":"Simone","family":"Ferrero","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Dreyling","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-3-20210128","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1200\/JCO.2008.16.8435","article-title":"Improvement of overall survival in advanced stage mantle cell lymphoma.","volume":"27","author":"Herrmann","year":"2009","journal-title":"J Clin Oncol"},{"key":"R2-3-20210128","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1182\/blood-2010-04-189977","article-title":"Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era.","volume":"117","author":"Perez-Galan","year":"2011","journal-title":"Blood"},{"key":"R3-3-20210128","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1182\/blood-2011-11-391474","article-title":"Whole transcriptome sequencing reveals recurrent NOTCH1 mutations in mantle cell lymphoma.","volume":"119","author":"Kridel","year":"2012","journal-title":"Blood"},{"key":"R4-3-20210128","doi-asserted-by":"crossref","first-page":"4939","DOI":"10.1182\/blood-2011-07-370122","article-title":"Genome-wide miRNA profiling of mantle cell lymphoma reveals a distinct subgroup with poor prognosis.","volume":"119","author":"Iqbal","year":"2012","journal-title":"Blood"},{"key":"R5-3-20210128","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.ccr.2012.09.015","article-title":"The requirement for cyclin D function in tumor maintenance.","volume":"22","author":"Choi","year":"2012","journal-title":"Cancer Cell"},{"key":"R6-3-20210128","doi-asserted-by":"crossref","first-page":"2687","DOI":"10.1182\/blood-2008-03-147025","article-title":"Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group.","volume":"112","author":"Geisler","year":"2008","journal-title":"Blood"},{"key":"R7-3-20210128","first-page":"151","article-title":"Alternating Courses of 3x CHOP and 3x DHAP Plus Rituximab Followed by a High Dose ARA-C Containing Myeloablative Regimen and Autologous Stem Cell Transplantation (ASCT) Increases Overall Survival When Compared to 6 Courses of CHOP Plus Rituximab Followed by Myeloablative Radiochemotherapy and ASCT in Mantle Cell Lymphoma: Final Analysis of the MCL Younger Trial of the European Mantle Cell Lymphoma Network (MCL net).","volume":"120","author":"Hermine","year":"2012","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"R8-3-20210128","first-page":"152","article-title":"Clinical, Metabolic and Molecular Responses After 4 Courses of R-DHAP and After Autologous Stem Cell Transplantation for Untreated Mantle Cell Lymphoma Patients Included in the LyMa Trial, a Lysa Study.","volume":"120","author":"Le Gouill","year":"2012","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"R9-3-20210128","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1093\/annonc\/mds643","article-title":"ESMO Consensus conferences: guidelines on malignant lymphoma. part 2: marginal zone lymphoma, mantle cell lymphoma, peripheral T-cell lymphoma.","volume":"24","author":"Dreyling","year":"2013","journal-title":"Ann Oncol"},{"key":"R10-3-20210128","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1111\/j.1365-2141.2010.08228.x","article-title":"Ten-year follow-up after intense chemoimmunotherapy with Rituximab-HyperCVAD alternating with Rituximab-high dose methotrexatecytarabine (R-MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphoma.","volume":"150","author":"Romaguera","year":"2010","journal-title":"Br J Haematol"},{"key":"R11-3-20210128","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1111\/j.1365-2141.2011.08958.x","article-title":"Rituximab plus HyperCVAD alternating with high dose cytarabine and methotrexate for the initial treatment of patients with mantle cell lymphoma, a multicentre trial from Gruppo Italiano Studio Linfomi.","volume":"156","author":"Merli","year":"2012","journal-title":"Br J Haematol"},{"key":"R12-3-20210128","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1056\/NEJMoa1200920","article-title":"Treatment of older patients with mantle-cell lymphoma.","volume":"367","author":"Kluin-Nelemans","year":"2012","journal-title":"N Engl J Med"},{"key":"R13-3-20210128","doi-asserted-by":"crossref","first-page":"3064","DOI":"10.1182\/blood-2004-04-1323","article-title":"The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group.","volume":"104","author":"Forstpointner","year":"2004","journal-title":"Blood"},{"key":"R14-3-20210128","doi-asserted-by":"crossref","first-page":"2172","DOI":"10.1080\/10428190701618268","article-title":"Rituximab, gemcitabine and oxaliplatin: an effective regimen in patients with refractory and relapsing mantle cell lymphoma.","volume":"48","author":"Rodriguez","year":"2007","journal-title":"Leuk Lymphoma"},{"key":"R15-3-20210128","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1080\/10428190801993470","article-title":"Salvage chemotherapy with rituximab DHAP for relapsed non-Hodgkin lymphoma: a phase II trial in the North Central Cancer Treatment Group.","volume":"49","author":"Witzig","year":"2008","journal-title":"Leuk Lymphoma"},{"key":"R16-3-20210128","doi-asserted-by":"crossref","first-page":"3383","DOI":"10.1200\/JCO.2005.08.100","article-title":"Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkins lymphoma.","volume":"23","author":"Rummel","year":"2005","journal-title":"J Clin Oncol"},{"key":"R19-3-20210128","doi-asserted-by":"crossref","first-page":"4144","DOI":"10.1182\/blood-2008-10-184200","article-title":"Mature results of the M. D. Anderson Cancer Center risk-adapted transplantation strategy in mantle cell lymphoma.","volume":"113","author":"Tam","year":"2009","journal-title":"Blood"},{"key":"R20-3-20210128","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.1002\/cncr.25055","article-title":"Durable responses with the metronomic rituximab and thalidomide plus prednisone, etoposide, procarbazine, and cyclophosphamide regimen in elderly patients with recurrent mantle cell lymphoma.","volume":"116","author":"Ruan","year":"2010","journal-title":"Cancer"},{"key":"R22-3-20210128","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1200\/JCO.2005.03.108","article-title":"Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkins lymphoma.","volume":"23","author":"Goy","year":"2005","journal-title":"J Clin Oncol"},{"key":"R23-3-20210128","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1200\/JCO.2005.02.050","article-title":"Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkins lymphoma and mantle cell lymphoma.","volume":"23","author":"OConnor","year":"2005","journal-title":"J Clin Oncol"},{"key":"R24-3-20210128","doi-asserted-by":"crossref","first-page":"4867","DOI":"10.1200\/JCO.2006.07.9665","article-title":"Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma.","volume":"24","author":"Fisher","year":"2006","journal-title":"J Clin Oncol"},{"key":"R25-3-20210128","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1093\/annonc\/mdn656","article-title":"Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study.","volume":"20","author":"Goy","year":"2009","journal-title":"Ann Oncol"},{"key":"R26-3-20210128","doi-asserted-by":"crossref","first-page":"2442","DOI":"10.1002\/cncr.25792","article-title":"Phase 2 trial of rituximab and bortezomib in patients with relapsed or refractory mantle cell and follicular lymphoma.","volume":"117","author":"Baiocchi","year":"2011","journal-title":"Cancer"},{"key":"R27-3-20210128","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.3324\/haematol.2011.041392","article-title":"Bortezomib combined with rituximab and dexamethasone is an active regimen for patients with relapsed and chemotherapy-refractory mantle cell lymphoma.","volume":"96","author":"Lamm","year":"2011","journal-title":"Haematologica"},{"key":"R28-3-20210128","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1080\/10428190902856790","article-title":"A novel regimen combining high dose cytarabine and bortezomib has activity in multiply relapsed and refractory mantle cell lymphoma - long-term results of a multicenter observation study.","volume":"50","author":"Weigert","year":"2009","journal-title":"Leuk Lymphoma"},{"key":"R29-3-20210128","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1158\/1078-0432.CCR-10-1498","article-title":"Phase I trial of weekly and twice-weekly bortezomib with rituximab, cyclophosphamide, and prednisone in relapsed or refractory non-Hodgkin lymphoma.","volume":"17","author":"Gerecitano","year":"2011","journal-title":"Clin Cancer Res"},{"key":"R30-3-20210128","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1182\/blood-2010-11-314708","article-title":"The combination of bendamustine, bortezomib, and rituximab for patients with relapsedrefractory indolent and mantle cell non-Hodgkin lymphoma.","volume":"117","author":"Friedberg","year":"2011","journal-title":"Blood"},{"key":"R31-3-20210128","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3109\/10428194.2010.546015","article-title":"A phase II study of bortezomib and gemcitabine in relapsed mantle cell lymphoma from the National Cancer Institute of Canada Clinical Trials Group (IND 172).","volume":"52","author":"Kouroukis","year":"2011","journal-title":"Leuk Lymphoma"},{"key":"R32-3-20210128","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1200\/JCO.2010.31.1142","article-title":"Bortezomib plus CHOP-rituximab for previously untreated diffuse large B-cell lymphoma and mantle cell lymphoma.","volume":"29","author":"Ruan","year":"2011","journal-title":"J Clin Oncol"},{"key":"R33-3-20210128","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1093\/annonc\/mdr450","article-title":"Combination of rituximab, bortezomib, doxorubicin, dexamethasone and chlorambucil (RiPADC) as first-line therapy for elderly mantle cell lymphoma patients: results of a phase II trial from the GOELAMS.","volume":"23","author":"Houot","year":"2012","journal-title":"Ann Oncol"},{"key":"R34-3-20210128","first-page":"153","article-title":"Mature Results From ECOG Study E1405 - A Phase II Study of VcR-CVAD with Maintenance Rituximab for Previously Untreated Mantle Cell Lymphoma.","volume":"120","author":"Kahl","year":"2012","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"R35-3-20210128","doi-asserted-by":"crossref","first-page":"3822","DOI":"10.1200\/JCO.2008.20.7977","article-title":"Phase III study to evaluate temsirolimus compared with investigators choice therapy for the treatment of relapsed or refractory mantle cell lymphoma.","volume":"27","author":"Hess","year":"2009","journal-title":"J Clin Oncol"},{"key":"R36-3-20210128","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/S1470-2045(11)70062-6","article-title":"Temsirolimus and rituximab in patients with relapsed or refractory mantle cell lymphoma: a phase 2 study.","volume":"12","author":"Ansell","year":"2011","journal-title":"Lancet Oncol"},{"key":"R37-3-20210128","first-page":"2697","article-title":"Temsirolimus in Combination with Bendamustine and Rituximab for the Treatment of Relapsed Mantle Cell and Follicular Lymphoma: Report on An Ongoing Phase III Trial.","volume":"118","author":"Hess","year":"2011","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"R38-3-20210128","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.3324\/haematol.2011.053173","article-title":"A multicenter phase II trial (SAKK 3606) of single-agent everolimus (RAD001) in patients with relapsed or refractory mantle cell lymphoma.","volume":"97","author":"Renner","year":"2012","journal-title":"Haematologica"},{"key":"R39-3-20210128","doi-asserted-by":"crossref","first-page":"4952","DOI":"10.1200\/JCO.2007.15.3429","article-title":"Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkins lymphoma.","volume":"26","author":"Wiernik","year":"2008","journal-title":"J Clin Oncol"},{"key":"R40-3-20210128","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1093\/annonc\/mdq626","article-title":"An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkins lymphoma.","volume":"22","author":"Witzig","year":"2011","journal-title":"Ann Oncol"},{"key":"R41-3-20210128","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1111\/bjh.12008","article-title":"Single-agent lenalidomide in relapsedrefractory mantle cell lymphoma: results from a UK phase II study suggest activity and possible gender differences.","volume":"159","author":"Eve","year":"2012","journal-title":"Br J Haematol"},{"key":"R42-3-20210128","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/S1470-2045(12)70200-0","article-title":"Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 12 clinical trial.","volume":"13","author":"Wang","year":"2012","journal-title":"Lancet Oncol"},{"key":"R43-3-20210128","doi-asserted-by":"crossref","first-page":"416","DOI":"10.3324\/haematol.2011.051813","article-title":"Salvage treatment with lenalidomide and dexamethasone in relapsedrefractory mantle cell lymphoma: clinical results and effects on microenvironment and neo-angiogenic biomarkers.","volume":"97","author":"Zaja","year":"2012","journal-title":"Haematologica"},{"key":"R44-3-20210128","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1182\/blood-2004-03-1091","article-title":"Antitumor activity of rituximab plus thalidomide in patients with relapsedrefractory mantle cell lymphoma.","volume":"104","author":"Kaufmann","year":"2004","journal-title":"Blood"},{"key":"R45-3-20210128","first-page":"1794","article-title":"Efficacy and Safety of Thalidomide In Mantle Cell Lymphoma: Results of the French ATU Program.","volume":"116","author":"Harel","year":"2010","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"R46-3-20210128","doi-asserted-by":"crossref","first-page":"5213","DOI":"10.1200\/JCO.2009.21.8545","article-title":"Phase II study of yttrium-90-ibritumomab tiuxetan in patients with relapsed or refractory mantle cell lymphoma.","volume":"27","author":"Wang","year":"2009","journal-title":"J Clin Oncol"},{"key":"R47-3-20210128","doi-asserted-by":"crossref","first-page":"3119","DOI":"10.1200\/JCO.2012.42.2444","article-title":"Phase II study of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone immunochemotherapy followed by yttrium-90-ibritumomab tiuxetan in untreated mantle-cell lymphoma: Eastern Cooperative Oncology Group Study E1499.","volume":"30","author":"Smith","year":"2012","journal-title":"J Clin Oncol"},{"key":"R48-3-20210128","doi-asserted-by":"crossref","first-page":"254","DOI":"10.3109\/10428194.2011.608445","article-title":"A phase I study evaluating ibritumomab tiuxetan (Zevalin) in combination with bortezomib (Velcade) in relapsedrefractory mantle cell and low grade B-cell non-Hodgkin lymphoma.","volume":"53","author":"Beaven","year":"2012","journal-title":"Leuk Lymphoma"},{"key":"R49-3-20210128","first-page":"904","article-title":"Interim Results of an International, Multicenter, Phase 2 Study of Brutons Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765), in Relapsed or Refractory Mantle Cell Lymphoma (MCL): Durable Efficacy and Tolerability with Longer Follow-up.","volume":"120","author":"Wang","year":"2012","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"R50-3-20210128","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/bjh.12206","article-title":"The Bruton tyrosine kinase (BTK) inhibitor PCI-32765 synergistically increases proteasome inhibitor activity in diffuse large-B cell lymphoma (DLBCL) and mantle cell lymphoma (MCL) cells sensitive or resistant to bortezomib.","volume":"161","author":"Dasmahapatra","year":"2013","journal-title":"Br J Haematol"},{"key":"R51-3-20210128","first-page":"1777","article-title":"Clinical Safety and Activity In a Phase 1 Study of CAL-101, An Isoform-Selective Inhibitor of Phosphatidylinositol 3-Kinase P110delta, In Patients with Relapsed or Refractory Non-Hodgkin Lymphoma.","volume":"116","author":"Kahl","year":"2010","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"R52-3-20210128","first-page":"2878","article-title":"Promising Efficacy with the New Anti-CD20 Antibody GA101 In Heavily Pre-Treated NHL Patients - First Results From a Phase II Study In Patients with RelapsedRefractory DLBCL and MCL.","volume":"116","author":"Cartron","year":"2010","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"R53-3-20210128","first-page":"1647","article-title":"Safety, Tolerability and Activity of Ofatumumab, Bendamustine and Dexamethasone Combination As First-Line Treatment of Mantle-Cell Lymphoma in the Elderly: A Multicenter Study.","volume":"118","author":"Magni","year":"2011","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"R54-3-20210128","first-page":"3692","article-title":"Phase III Trial of OfatumumabLenalidamide for Patients with RelaspedRefractory B-Cell Non-Hodgkin Lymphoma: High Response Rate in Indolent Lymphoma.","volume":"120","author":"Vose","year":"2012","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"R55-3-20210128","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1126\/science.1158545","article-title":"Tumor regression in cancer patients by very low doses of a T cell-engaging antibody.","volume":"321","author":"Bargou","year":"2008","journal-title":"Science"},{"key":"R56-3-20210128","first-page":"2880","article-title":"Treatment of Patients with Non-Hodgkin Lymphoma (NHL) with CD19CD3 Bispecific Antibody Blinatumomab (MT103): Double-Step Dose Increase to Continuous Infusion of 60gm2d Is Tolerable and Highly Effective.","volume":"116","author":"Viardot","year":"2010","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"R57-3-20210128","first-page":"56","article-title":"e al. A Phase I Study of the Anti-CD79b Antibody-Drug Conjugate (ADC) DCDS4501A Targeting CD79b in Relapsed or Refractory B-Cell Non-Hodgkins Lymphoma (NHL).","volume":"120","author":"Palanca-Wessels","year":"2012","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"R58-3-20210128","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1200\/JCO.2009.24.1570","article-title":"Flavopiridol, fludarabine, and rituximab in mantle cell lymphoma and indolent B-cell lymphoproliferative disorders.","volume":"28","author":"Lin","year":"2010","journal-title":"J Clin Oncol"},{"key":"R59-3-20210128","doi-asserted-by":"crossref","first-page":"3388","DOI":"10.1158\/1078-0432.CCR-10-2876","article-title":"Phase I trial of bortezomib (PS-341; NSC 681239) and alvocidib (flavopiridol; NSC 649890) in patients with recurrent or refractory B-cell neoplasms.","volume":"17","author":"Holkova","year":"2011","journal-title":"Clin Cancer Res"},{"key":"R60-3-20210128","doi-asserted-by":"crossref","first-page":"4597","DOI":"10.1182\/blood-2011-10-388298","article-title":"Selective CDK46 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma.","volume":"119","author":"Leonard","year":"2012","journal-title":"Blood"},{"key":"R61-3-20210128","first-page":"304","article-title":"The BCL-2-Specific BH3-Mimetic ABT-199 (GDC-0199) Is Active and Well Tolerated in Patients with Relapsed Non-Hodgkin Lymphoma: Interim Results of a Phase I Study.","volume":"120","author":"Davids","year":"2012","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"R62-3-20210128","first-page":"55","article-title":"A Phase II Multicenter Study of the Histone Deacetylase Inhibitor (HDACi) Abexinostat (PCI-24781) in RelapsedRefractory Follicular Lymphoma (FL) and Mantle Cell Lymphoma (MCL).","volume":"120","author":"Evens","year":"2012","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"R63-3-20210128","doi-asserted-by":"crossref","first-page":"2695","DOI":"10.1093\/annonc\/mds054","article-title":"Reduced-intensity conditioning allogeneic stem cell transplantation for relapsedrefractory mantle cell lymphoma: a multicenter experience.","volume":"23","author":"Le Gouill","year":"2012","journal-title":"Ann Oncol"},{"key":"R64-3-20210128","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2013.01.009","article-title":"Allogeneic hematopoietic cell transplantation for chemotherapy-unresponsive mantle cell lymphoma: a cohort analysis from the center for international blood and marrow transplant research.","volume":"19","author":"Hamadani","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"key":"R65-3-20210128","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1038\/bmt.2012.62","article-title":"Dose-escalated radioimmunotherapy as part of reduced intensity conditioning for allogeneic transplantation in patients with advanced high-grade non-Hodgkin lymphoma.","volume":"47","author":"Bethge","year":"2012","journal-title":"Bone Marrow Transplant"},{"key":"R66-3-20210128","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1182\/blood-2010-12-324392","article-title":"90Y-Ibritumomab tiuxetan, fludarabine, and TBI-based nonmyeloablative allogeneic transplantation conditioning for patients with persistent high-risk B-cell lymphoma.","volume":"118","author":"Gopal","year":"2011","journal-title":"Blood"},{"key":"R67-3-20210128","first-page":"2677","article-title":"Cell Proliferation (Ki-67) As Prognostic Marker in Mantle Cell Lymphoma.","volume":"120","author":"Hoster","year":"2012","journal-title":"Blood (ASH Annual Meeting Abstracts)"}],"container-title":["Current Opinion in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CCO.0b013e328363df0b","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,15]],"date-time":"2024-05-15T02:11:47Z","timestamp":1715739107000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00001622-201309000-00003"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,9]]},"references-count":64,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2013]]}},"URL":"https:\/\/doi.org\/10.1097\/cco.0b013e328363df0b","relation":{},"ISSN":["1040-8746"],"issn-type":[{"value":"1040-8746","type":"print"}],"subject":[],"published":{"date-parts":[[2013,9]]}}}